CUE · Insider trading · 13F holders · Congress trades
Cue Biopharma, Inc. (CUE)
Who is buying and selling CUE: company insiders on SEC Form 4, hedge funds and superinvestors on Form 13F, and members of Congress under the STOCK Act. Every figure links to the filing or page it comes from.
- 13F filers holding
- 5
- Insider buys, 90 days
- $0
- Insider sales, 90 days
- $2.4M
- Congress trades, 12 months
- 0
CUE at a glance
- Between Aug 1, 2026 and Oct 29, 2026, 3 CUE insiders filed 6 sales worth $2.4M on SEC Form 4, and no open-market purchases.
- 5 13F filers hold CUE among their 50 largest positions, worth $19.4M combined. The biggest bets by portfolio weight are Lion Point Capital, LP (8.0%), Bleichroeder LP (2.1%) and Diadema Partners LP (0.6%). In their latest 13Fs, 3 managers opened a new position and 0 added to one.
- No member of Congress has disclosed a trade in CUE.
- CUE last closed at $21.45 on Oct 29, 2026.
CUE insider trading
Between Aug 1, 2026 and Oct 29, 2026, 3 CUE insiders filed 6 sales worth $2.4M on SEC Form 4, and no open-market purchases.
| Filed | Insider | Role | Trade | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|---|
| Oct 14, 2026 | Lin Shao-Lee | Chief Executive Officer, Director | Sale | 11,087 | $27.55 | $305K | SEC |
| Oct 14, 2026 | Ray Sumita | Chief Legal Compliance Officer, Corporate Secretary | Sale | 1,844 | $28.05 | $52K | SEC |
| Oct 14, 2026 | Meluzio Michael Vincent | VP, Prin. Accounting Officer | Sale | 1,144 | $28.05 | $32K | SEC |
| Aug 17, 2026 | Ray Sumita | Chief Legal Compliance Officer, Corporate Secretary | Sale | 8,829 | $30.09 | $266K | SEC |
| Aug 17, 2026 | Meluzio Michael Vincent | VP, Prin. Accounting Officer | Sale | 5,628 | $30.09 | $169K | SEC |
| Aug 14, 2026 | Lin Shao-Lee | Chief Executive Officer, Director | Sale | 58,258 | $27.58 | $1.6M | SEC |
Who owns CUE? Hedge funds and superinvestors
5 13F filers hold CUE among their 50 largest positions, worth $19.4M combined. The biggest bets by portfolio weight are Lion Point Capital, LP (8.0%), Bleichroeder LP (2.1%) and Diadema Partners LP (0.6%). In their latest 13Fs, 3 managers opened a new position and 0 added to one.
| Manager | % of portfolio | Value | Shares | Last quarter | 13F |
|---|---|---|---|---|---|
| Bleichroeder LPHedge fund | 2.1% | $11.7M | 370,682 | — | Q2 2026 |
| Tetragon Partners GP LtdHedge fund | 0.5% | $3.0M | 93,819 | New | Q2 2026 |
| Lion Point Capital, LPHedge fund | 8.0% | $1.7M | 52,928 | New | Q2 2026 |
| Squadron Capital Management LLCHedge fund | 0.5% | $1.6M | 50,000 | New | Q2 2026 |
| Diadema Partners LPHedge fund | 0.6% | $1.5M | 48,369 | — | Q2 2026 |
Each manager counts with its latest 13F (Q2 2026: 5). Screen CUE in the grand portfolio →
CUE stock trades by members of Congress
No member of Congress has disclosed a trade in CUE.
CUE questions and answers
Are insiders buying CUE stock?
Between Aug 1, 2026 and Oct 29, 2026, 3 CUE insiders filed 6 sales worth $2.4M on SEC Form 4, and no open-market purchases.
Which hedge funds own CUE?
5 13F filers hold CUE among their 50 largest positions, worth $19.4M combined. The biggest bets by portfolio weight are Lion Point Capital, LP (8.0%), Bleichroeder LP (2.1%) and Diadema Partners LP (0.6%). In their latest 13Fs, 3 managers opened a new position and 0 added to one.
Has Congress traded CUE?
No member of Congress has disclosed a trade in CUE.
Who is the largest holder of CUE?
Among 13F filers, Bleichroeder LP reports the largest CUE position, $11.7M (370,682 shares) in its Q2 2026 13F. The biggest bet by portfolio weight is Lion Point Capital, LP's: 8.0% of its portfolio.
Cite or share this
Free to use with a link back. The data updates every filing day.